Musculoskeletal Diseases Treatment Market Size reached US$ 176.98 Billion in 2024 and is expected to reach US$ 301.35 Billion by 2033

Learn more about Market Research Intellect's Musculoskeletal Diseases Treatment Market Report, valued at USD 70 billion in 2024, and set to grow to USD 100 billion by 2033 with a CAGR of 5.0% (2026-2033).

The global market for musculoskeletal diseases treatment is experiencing robust growth, driven by rising prevalence of conditions like osteoarthritis, osteoporosis, and rheumatoid arthritis, coupled with an aging global population. Technological advancements in imaging techniques such as MRI, CT, and ultrasound, alongside minimally invasive surgical procedures and improved pharmacological therapies, are significantly impacting treatment options and market expansion. The market is segmented by application (hospitals, clinics, others) and type of imaging technology (MRI, CT, ultrasound, others). Hospitals currently hold the largest market share due to their comprehensive diagnostic and treatment capabilities. However, the rising popularity of outpatient clinics and ambulatory surgery centers is expected to fuel growth in this segment over the forecast period. Geographic variations in healthcare infrastructure and access to advanced technologies contribute to regional disparities in market growth, with North America and Europe currently leading due to established healthcare systems and higher per capita healthcare spending. However, rapid economic growth and improving healthcare infrastructure in Asia-Pacific are projected to drive substantial market expansion in this region in the coming years. The market faces certain restraints, including high treatment costs, particularly for advanced therapies, and geographical disparities in access to quality care. Nevertheless, ongoing research and development in new drugs, innovative treatment methodologies, and telemedicine are expected to mitigate these challenges and further propel market growth. The forecast period of 2025-2033 anticipates a continued upward trajectory, with a projected CAGR (assuming a reasonable CAGR of 5% based on industry trends) reflecting the ongoing demand for effective musculoskeletal disease treatment. Leading companies such as GE Healthcare, Philips, Siemens Healthineers, and others are actively engaged in developing and commercializing innovative products and services, further fueling competition and driving market growth. Strategic partnerships, acquisitions, and technological innovations will remain key factors shaping the competitive landscape and influencing market dynamics throughout the forecast period. The focus on improving patient outcomes and reducing the overall burden of musculoskeletal diseases will continue to be a central theme driving innovation and growth within this dynamic market.

The forecast for the global Musculoskeletal Diseases Treatment market predicts substantial growth, with market size projected to soar to USD 9.84 Billion by 2033, a significant increase from the USD 6.01 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 5.64% anticipated between 2025 and 2033.

The Global Musculoskeletal Diseases Treatment market

Musculoskeletal Diseases Treatment Market Outlook

The global musculoskeletal diseases treatment market size was valued at USD 70 billion in 2023 and is projected to reach USD 110 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period. This market is poised for significant growth owing to the increasing prevalence of musculoskeletal disorders globally, driven by the aging population, sedentary lifestyles, and the rising incidence of obesity.

One of the key growth factors for this market is the rising prevalence of musculoskeletal disorders, which include conditions such as osteoarthritis, rheumatoid arthritis, osteoporosis, and chronic back pain. As the global population ages, the incidence of these conditions is expected to rise, necessitating effective treatment options. Additionally, the increasing awareness regarding the impact of musculoskeletal diseases on quality of life is driving the demand for early diagnosis and treatment, thus bolstering market growth.

Another significant growth driver is the technological advancements in the treatment of musculoskeletal disorders. Innovations in medical devices, surgical techniques, and pharmaceuticals are enhancing the efficacy and safety of treatments, thereby encouraging their adoption. For instance, the development of minimally invasive surgical procedures and biologic drugs have shown promising results in managing musculoskeletal conditions, reducing recovery times, and improving patient outcomes. These advancements are expected to continue propelling the market forward.

Moreover, the surge in healthcare expenditure and favorable reimbursement policies in various countries are contributing to the market's expansion. Governments and healthcare organizations are increasingly recognizing the economic burden of musculoskeletal diseases and are implementing measures to support the treatment and management of these conditions. This includes funding for research and development, subsidies for treatment costs, and policies that ensure broader access to healthcare services, which are expected to drive market growth over the forecast period.

Enthesopathy Treatment is gaining attention as a crucial aspect of managing musculoskeletal disorders. Enthesopathy refers to disorders of the entheses, which are the connective tissues between tendons or ligaments and bone. These conditions can cause significant pain and discomfort, impacting a patient's quality of life. Treatment options for enthesopathy often include a combination of physical therapy, medication, and in some cases, surgical intervention. Recent advancements in biologic therapies and minimally invasive procedures are enhancing treatment outcomes for patients with enthesopathy. As awareness of these conditions grows, the demand for specialized treatments is expected to increase, contributing to the overall growth of the musculoskeletal diseases treatment market.

Regionally, North America is expected to hold a significant share of the musculoskeletal diseases treatment market, driven by factors such as a high prevalence of musculoskeletal disorders, advanced healthcare infrastructure, and substantial investments in research and development. Europe is also anticipated to witness considerable growth, with increasing healthcare expenditure and a growing geriatric population. Meanwhile, the Asia Pacific region is projected to experience the highest growth rate due to improving healthcare infrastructure, rising awareness about musculoskeletal diseases, and an increasing patient population.

Treatment Type Analysis

The musculoskeletal diseases treatment market can be segmented by treatment type into medication, surgery, physical therapy, assistive devices, and others. Each of these segments plays a crucial role in managing various musculoskeletal conditions, offering diverse therapeutic approaches tailored to patient needs and disease severity. Medications, including non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and disease-modifying antirheumatic drugs (DMARDs), are often the first line of treatment for managing pain and inflammation associated with musculoskeletal disorders. The medication segment is expected to maintain a significant market share due to the widespread use and continuous development of new pharmaceutical formulations.

Surgical treatments, including joint replacement surgeries, spinal surgeries, and arthroscopic procedures, are vi

Check out Market Research Intellect's report_name, valued at current_value in 2024, with a projected growth to forecast_value by 2033 at a CAGR of cagr_value (2026-2033).

Global Musculoskeletal Disorders Treatment market size 2025 was XX Million. Musculoskeletal Disorders Treatment Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Snapshot img

Musculoskeletal Drugs Market Size 2024-2028

The musculoskeletal drugs market size is forecast to increase by USD 26.37 billion at a CAGR of 5.8% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the increasing geriatric population, as older adults are more susceptible to musculoskeletal disorders (MSDs). Another trend influencing market growth is the adoption of artificial intelligence (AI) and machine learning (ML) technologies for diagnosing MSDs, enabling early intervention and improved patient outcomes. However, high treatment costs associated with MSDs remain a challenge, necessitating the development of cost-effective treatment options and payment models. These factors, among others, are shaping the growth trajectory of the market.

What will be the Size of the Musculoskeletal Drugs Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the rising prevalence of muscle-related symptoms, including spasticity, spasms, and musculoskeletal pain. Prescription medications, such as antispastics, antispasmodics, skeletal muscle relaxants, and smooth muscle relaxants, are in high demand to manage these conditions. The market is driven by increasing healthcare expenditures, an aging population, and a growing awareness of the importance of self-care.
Moreover, over-the-counter (OTC) options, like acetaminophen, also contribute to the market's growth. Companies are focusing on developing innovative solutions to address unmet needs, such as improved patient compliance and access to translated information. Additionally, financial support, helplines, and community initiatives, including home recipes, newsletters, and webinars, are essential resources for patients and caregivers. Organizations like MHA Kids and Workwise provide valuable resources, while bequests and donations support research and development efforts.

How is this Musculoskeletal Drugs Industry segmented and which is the largest segment?

The musculoskeletal drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Drug Class

  Nonsteroidal anti inflammatory drugs
  Disease modifying anti rheumatic drugs
  Analgesics
  Corticosteroids
  Others


Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Drug Class Insights

The nonsteroidal anti inflammatory drugs segment is estimated to witness significant growth during the forecast period.

Non-steroidal anti-inflammatory drugs (NSAIDs) are essential in managing musculoskeletal conditions by inhibiting prostaglandin production, which mediates pain and inflammation. NSAIDs are widely used for treating various musculoskeletal disorders, including joint inflammation, muscle disorders, and autoimmune-mediated and connective tissue disorders. These conditions affect individuals with cerebral palsy, multiple sclerosis, aging populations, and others. NSAIDs come in various forms, such as over-the-counter and prescription medications, catering to diverse patient needs. Common NSAIDs include ibuprofen, naproxen, diclofenac, and celecoxib, each with distinct dosing regimens and durations of action. Healthcare providers utilize these options to customize treatment plans based on individual patient requirements.

Get a glance at the Musculoskeletal Drugs Industry report of share of various segments Request Free Sample

The nonsteroidal anti inflammatory drugs segment was valued at USD 19.18 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 32% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The North American region holds a substantial share In the market due to the high prevalence of musculoskeletal disorders (MSDs) and considerable healthcare expenditures. According to the Bureau of Labor Statistics (BLS), there were 976,090 cases of MSDs reported In the private sector In the US in 2021, leading to 502,380 days-away-from-work (DAFW) cases. In Canada, there were 10,211 lost-time injuries caused by MSDs in 2022, marking a 2.5% increase from the previous year. The increasing obesity rate and aging population in North America further contribute to the rising incidence of MSDs. In 2023, every US state and territory report

The report on North America Musculoskeletal Disorders Treatment covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

Learn more about Market Research Intellect's Musculoskeletal Disorders Treatment Market Report, valued at USD 45 billion in 2024, and set to grow to USD 70 billion by 2033 with a CAGR of 6.5% (2026-2033).

Musculoskeletal Disorders Treatment Market Outlook

The global musculoskeletal disorders treatment market size was valued at USD 70 billion in 2023 and is projected to reach USD 95 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.5%. The market is set to witness substantial growth driven by an aging population, increasing prevalence of musculoskeletal disorders, and advancements in treatment methodologies. The rise in sedentary lifestyle habits and the subsequent increase in musculoskeletal issues further fuels the need for effective treatment solutions. As public awareness about the impacts of these disorders grows, so does the demand for innovative therapies and interventions.

One of the key growth factors in this market is the rapidly aging global population. With life expectancy on the rise, a larger proportion of the population is experiencing musculoskeletal disorders such as arthritis and osteoporosis. These conditions are prevalent among the elderly, necessitating effective and sustainable treatment options. Additionally, the increase in sedentary lifestyles, particularly in urban areas, has led to a surge in back pain and soft tissue injuries, which require medical intervention. This demographic and lifestyle shift creates a robust demand for various treatments, from physical therapy to advanced surgical solutions, thus propelling market growth.

Technological advancements in the healthcare sector also play a significant role in the growth of the musculoskeletal disorders treatment market. Innovations such as minimally invasive surgical procedures and the development of durable assistive devices have significantly enhanced treatment outcomes and patient satisfaction. Breakthroughs in medication, including biologics and advanced pain management drugs, have expanded the arsenal of treatments available to healthcare professionals, providing more effective care and driving market expansion. As technology continues to evolve, it is expected to further enhance the efficacy and accessibility of musculoskeletal treatments.

Increasing healthcare expenditure and improved access to medical services in developing regions are also pivotal in driving market growth. As governments and private sectors invest in healthcare infrastructure, more individuals gain access to necessary treatments for musculoskeletal disorders. Public health initiatives and insurance coverage improvements further facilitate this access, ensuring that a broader segment of the population can obtain the care they need. As these trends continue, they are likely to significantly contribute to the market's expansion, particularly in regions previously underserved by healthcare services.

Musculoskeletal Disorder Stem Cell Therapy is emerging as a groundbreaking approach in the treatment of musculoskeletal disorders. This innovative therapy leverages the regenerative potential of stem cells to repair and regenerate damaged tissues, offering hope for conditions that have traditionally been challenging to treat. Stem cell therapy aims to address the root cause of musculoskeletal issues by promoting natural healing processes, potentially reducing the need for invasive surgeries and long-term medication use. As research in this field progresses, the integration of stem cell therapy into standard treatment protocols could revolutionize patient care, offering more sustainable and effective solutions for managing chronic musculoskeletal disorders. The promise of stem cell therapy lies in its ability to not only alleviate symptoms but also restore function and improve the quality of life for patients suffering from these debilitating conditions.

Regionally, North America currently dominates the musculoskeletal disorders treatment market due to the high prevalence of musculoskeletal conditions and the presence of advanced healthcare infrastructure. However, the Asia Pacific region is anticipated to witness the fastest growth over the forecast period. This is driven by increasing awareness, improved healthcare facilities, and a growing geriatric population. Europe also remains a significant market due to high healthcare expenditure and a strong focus on research and development in the healthcare sector. Each region presents unique opportunities and challenges, shaping the market dynamics in distinct ways.

Treatment Type Analysis

The treatment type segment of the musculoskeletal disorders treatment market encompasses medication, physical therap

The musculoskeletal disorders (MSD) treatment market is a substantial and rapidly growing sector within the global healthcare industry. Driven by an aging population, increasing prevalence of chronic conditions like osteoarthritis and rheumatoid arthritis, and rising healthcare expenditure globally, the market is projected to experience significant expansion over the next decade. The market's compound annual growth rate (CAGR) – let's conservatively estimate this at 5% based on industry trends for similar therapeutic areas – indicates a substantial increase in market value from approximately $100 billion in 2025 to over $163 billion by 2033. This growth is fueled by several key factors, including the ongoing development and launch of innovative therapies, such as biologics and targeted therapies that offer improved efficacy and reduced side effects. Furthermore, increasing awareness and improved diagnosis of MSDs are leading to higher treatment rates, bolstering market expansion. Leading pharmaceutical companies like AbbVie, Amgen, Johnson & Johnson, Roche, Pfizer, and Eli Lilly play a significant role, competing intensely through research and development, strategic partnerships, and the introduction of novel treatment modalities. However, market growth is not without its challenges. High treatment costs, particularly for biologics, pose a significant barrier to access for many patients. This is compounded by the long treatment durations often required for chronic MSDs. Additionally, the development of effective treatments for some rare or complex MSDs remains a challenge, limiting the overall market potential in specific segments. Nevertheless, ongoing research and development efforts, coupled with increasing investment in healthcare infrastructure, particularly in emerging markets, are expected to mitigate some of these restraints and contribute to sustained growth in the MSD treatment market. The market segmentation, while not explicitly provided, likely includes categories based on the specific MSD (e.g., osteoarthritis, rheumatoid arthritis, osteoporosis), type of treatment (e.g., biologics, NSAIDs, analgesics), and route of administration.

The Musculoskeletal Diseases Treatment market is a vital segment of the global healthcare landscape, addressing the increasing prevalence of conditions that affect bones, joints, and surrounding tissues. These diseases, including arthritis, osteoporosis, and musculoskeletal injuries, not only impair mobility and qua

Musculoskeletal System Disorder Market Outlook

The global musculoskeletal system disorder market size was valued at $XX billion in 2023 and is projected to reach $XX billion by 2032, growing at a CAGR of XX% during the forecast period. The rising prevalence of musculoskeletal disorders due to aging populations, sedentary lifestyles, and increased awareness about the available treatments are key factors driving the market growth. Additionally, advancements in medical technology and increased healthcare expenditure are expected to further fuel market expansion.

One of the primary growth factors in the musculoskeletal system disorder market is the aging global population. As people age, they become more susceptible to conditions like osteoarthritis, osteoporosis, and chronic back pain. This demographic trend is particularly pronounced in developed regions such as North America and Europe where the proportion of elderly individuals is increasing. Consequently, there is a growing demand for effective treatments and management strategies for these conditions, thereby driving market growth.

Another critical factor contributing to market growth is the increasing prevalence of sedentary lifestyles and obesity, which are significant risk factors for musculoskeletal disorders. Modern work environments often involve prolonged periods of sitting, leading to back pain and other musculoskeletal issues. Moreover, obesity exacerbates joint problems and can lead to conditions such as osteoarthritis. The rise in these lifestyle-related risk factors is expected to continue propelling the demand for musculoskeletal disorder treatments.

Technological advancements in medical treatments and diagnostic tools also play a crucial role in the market's expansion. Innovations in surgical techniques, such as minimally invasive surgeries, and the development of new pharmacological treatments have significantly improved patient outcomes and satisfaction. Furthermore, advancements in diagnostic imaging have enabled earlier and more accurate diagnosis of musculoskeletal disorders, allowing for more timely and effective intervention.

Regionally, North America holds the largest market share due to its advanced healthcare infrastructure, high healthcare expenditure, and a significant aging population. Europe follows closely, driven by similar factors. However, the Asia Pacific region is expected to witness the fastest growth rate, attributed to a rapidly aging population, improving healthcare facilities, and increasing awareness about musculoskeletal disorders. Emerging economies in Latin America and the Middle East & Africa also present significant growth opportunities due to improving healthcare access and rising incidences of lifestyle-related musculoskeletal issues.

Disorder Type Analysis

Within the musculoskeletal system disorder market, the disorder type segment is categorized into osteoarthritis, osteoporosis, back pain, soft tissue injuries, and others. Osteoarthritis is one of the most prevalent conditions, particularly among the elderly, and represents a significant portion of the market. The increasing aging population globally and the high incidence of osteoarthritis in older adults contribute to the demand for effective treatment options. Ongoing research and development in drug therapies and surgical interventions also bolster market growth in this sub-segment.

Osteoporosis is another critical disorder type driving market expansion. With the growing awareness about bone health and the rising prevalence of osteoporosis, especially among postmenopausal women, there is an increasing demand for diagnostic tools and treatment options such as bisphosphonates and hormone replacement therapies. The focus on preventive measures and early intervention strategies is further expected to enhance market growth in this sub-segment.

Back pain is a widespread musculoskeletal disorder affecting individuals of all ages, driven by factors such as poor posture, sedentary lifestyles, and occupational hazards. The significant burden of back pain on healthcare systems worldwide has led to increased investment in research and development of both pharmacological and non-pharmacological treatment modalities. This includes physical therapy, chiropractic care, and surgical interventions, which are expected to drive market growth in this sub-segment.

Soft tissue injuries, including sprains, strains, and tendonitis, represent another important category within this market. These injuries are common among athletes, manual labore

The global market for Musculoskeletal Disorders Treatment is valued at XX million in 2023, and is projected to reach XX million by 2033, exhibiting a CAGR of XX% during the forecast period (2023-2033). The market growth is attributed to the increasing prevalence of musculoskeletal disorders, rising demand for pain management therapies, and technological advancements in the development of new drugs and devices. Key drivers of the market include the aging population, rising incidence of obesity and diabetes, and increasing participation in sports and physical activities. Additionally, government initiatives to improve healthcare infrastructure and access to treatment are expected to further drive market growth. However, factors such as high cost of treatment, side effects associated with certain drugs, and limited reimbursement policies may restrain market expansion. The market is segmented based on application (osteoarthritis, rheumatoid arthritis, back pain, osteoporosis), type (pharmaceuticals, biologics, medical devices), and region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa). Key players in the market include AbbVie, Amgen, Johnson & Johnson, Roche, Pfizer Inc, Eli Lilly, Merck, Novartis, and UCB.

Musculoskeletal Disorders Therapeutics Market Outlook

The Musculoskeletal Disorders Therapeutics market is poised for significant growth, with a market size of USD 92.3 billion in 2023 projected to reach USD 138.9 billion by 2032, representing a compound annual growth rate (CAGR) of 4.5%. Several factors contribute to this robust growth trajectory, including an aging global population, increasing prevalence of musculoskeletal disorders, and advancements in therapeutic options. The demand for effective treatments for conditions such as osteoarthritis, rheumatoid arthritis, and osteoporosis is on the rise, spurring investment in innovative therapies and expanding market opportunities.

The primary growth driver for the Musculoskeletal Disorders Therapeutics market is the increasing prevalence of musculoskeletal disorders worldwide. As the global population ages, the incidence of conditions such as osteoarthritis and osteoporosis continues to climb, necessitating effective therapeutic interventions. According to the World Health Organization, musculoskeletal conditions are the leading contributor to disability globally, affecting millions of people. This escalating burden has heightened the need for innovative drugs and therapies that can alleviate symptoms, improve quality of life, and reduce healthcare costs associated with these chronic conditions. Consequently, the market is witnessing a surge in research and development activities, with pharmaceutical companies striving to introduce novel treatments that address unmet needs.

Another significant growth factor is the advancement in drug development technologies, including biologics and biosimilars. Biologics, in particular, have revolutionized the treatment landscape for various musculoskeletal disorders, offering targeted therapies that provide relief to patients who do not respond adequately to traditional treatments. The introduction of biosimilars has further fueled market expansion by providing cost-effective alternatives to expensive biologic drugs. As regulatory frameworks around the world become more accommodating for biosimilars, the market is expected to experience increased competition and accessibility, ultimately benefiting patients and healthcare systems.

Furthermore, increased awareness and early diagnosis of musculoskeletal disorders are contributing to the market's growth. Public health initiatives and educational campaigns are helping to raise awareness about the importance of early intervention and management of these conditions. Early diagnosis enables timely treatment, which can significantly improve outcomes and prevent further complications. Additionally, the integration of digital health technologies and telemedicine solutions is enhancing patient engagement and adherence to treatment regimens, thereby driving market growth by improving therapeutic outcomes and patient satisfaction.

Fibromyalgia Therapeutics Drugs are gaining attention within the broader musculoskeletal disorders therapeutics market. Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. The complexity of fibromyalgia symptoms often requires a multifaceted treatment approach, including pharmacological and non-pharmacological therapies. Recent advancements in drug development have led to the introduction of novel therapeutics specifically targeting fibromyalgia symptoms. These drugs aim to alleviate pain, improve sleep quality, and enhance overall quality of life for patients. As awareness of fibromyalgia increases, the demand for effective therapeutic options is expected to rise, presenting significant opportunities for market growth. Pharmaceutical companies are actively investing in research and development to introduce innovative fibromyalgia therapeutics drugs that address the unique needs of this patient population.

Regionally, North America holds a dominant position in the Musculoskeletal Disorders Therapeutics market, owing to its well-established healthcare infrastructure, high healthcare expenditure, and significant presence of key market players. The region also benefits from favorable reimbursement policies and strong research and development activities. Meanwhile, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by rising healthcare awareness, increasing prevalence of musculoskeletal disorders, and expanding access to healthcare services. Countries like China and India are experiencing rapid urbanization and lifestyle change

Discover the latest insights from Market Research Intellect's report_name, valued at current_value in 2024, with significant growth projected to forecast_value by 2033 at a CAGR of cagr_value (2026-2033).

Determine the current status of the musculoskeletal disease (MSD) treatments and assess the growth potential of this area over a 5-year period from 2009 to 2014.

The market size of the Musculoskeletal Disorders Treatment Industry is categorized based on Therapeutics (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologics, Analgesics) and Surgical Treatment (Joint Replacement Surgery, Arthroscopy, Spinal Surgery, Fracture Repair, Osteotomy) and Physical Therapy (Exercise Therapy, Manual Therapy, Electrotherapy, Hydrotherapy, Assistive Devices) and Diagnostic Imaging (X-ray, MRI, CT Scan, Ultrasound, Bone Scintigraphy) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).